Plain-English translation of NCT07402343 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called , which is designed to help your immune system fight small cell lung cancer that has spread to your brain. works by activating your body's T cells—a type of immune cell—to attack cancer cells. Early results suggest this medication may be able to reach and work against tumors in the brain, which is important because many standard cancer drugs cannot easily get into the brain.
Brain tumors from lung cancer are difficult to treat because most standard chemotherapy drugs cannot reach the brain effectively, and radiation therapy alone often has limited success. This trial exists to see whether this new immunotherapy approach can work better against these brain tumors than current treatment options.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (through a vein in your arm), starting with a low dose in week 1, then a higher dose in weeks 2 and 3, and then every 2 weeks after that in 28-day cycles. You will need to visit the clinic regularly for infusions, blood tests, and brain imaging scans to see how the treatment is working. The study will track any side effects you experience and how your brain tumors respond to the medication over time.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Netherlands
Phase
Testing effectiveness
Sponsor
Maastricht University Medical Center
Collaborators
The Netherlands Cancer Institute, Erasmus Medical Center
Enrollment target
~35 participants
Started
August 2026
Primary completion
February 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lizza Hendriks, MD, PhD
Maastricht University Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.